Summit Therapeutics $SMMT
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-35
RECRUITING3
READOUTS ≤12 MONTHS0
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| AK112 Injection NCT06396065 |
P3 | Active, not recruiting | Non-Squamous Non-small Cell Lung Cancer | 420 | 2025-04-12 (-9 mo) |
| HARMONi-7 NCT06767514 |
P3 | Recruiting | Non-Small Cell Lung Cancer | 780 | 2028-04 |
| HARMONi-GI3 NCT07228832 |
P3 | Recruiting | Metastatic Colorectal Cancer (CRC) | 900 | 2028-05-31 |
| Ivonescimab Injection NCT05899608 |
P3 | Active, not recruiting | Non-Small Cell Lung Cancer | 1600 | 2028-12-31 (+15 mo) |
| SMT112-216 NCT07877194 |
P2 | Not yet recruiting | Renal Cell Carcinoma, Clear Cell | 100 | 2029-04-12 |
| HARMONi-GU1 NCT07815665 |
P2/3 | Recruiting | Metastatic Urothelial Carcinoma; Metastatic Urothelial Carcinoma (UC) | 800 | 2030-10-31 |